Skip to main content
. 2020 Oct 21;10:17960. doi: 10.1038/s41598-020-74344-x

Table 1.

Study population.

no-HRT N (%) Mean  ± SE (min–max) p value
Age (years)
At diagnosis 40 (100) 62.1 1.9 (37.0–93.2) 0.98
At end of follow up 40 (100) 68.9 1.8 (47.2–95.6) 0.57
Follow up time (years) 40 (100) 6.8 0.6 (1.2–16.4) 0.061
HRT duration (years) 40 (100) 5.0 0.7 (0.5–22.0)
Started and finished before diagnosis 11 (27.5) 3.7 12.8 (1.0–13.4)
Started after diagnosis 18 (45) 3.2 7.3 (0.5–9.6)
Started before, finished after diagnosis 11 (27.5) 9.4 1.5 (1.4–22.0)
Route
Oral/transdermal 25 (62.5)
Vaginal 12 (30)
Both 3 (7.5)
Estrogen agent
Estradiol 25 (62.5)
Conjugated estrogens 11 (27.5)
Multiple, other 4 (10)
Other characteristics
Body-Mass Index (kg/m2) 40 (100) 26.3 0.9 (18.0–47.0) 0.043*
Number of children (parity) 39 (97.5) 2.1 0.2 (0–6) 0.65
Radiographic characteristics (qualitative)
Calcified 18 (50) 0.35
Perilesional edema 3 (7.5) 0.54
T2-hyperintense 15 (38.5) 0.30
no–HRT N (%) Mean  ± SE (min–max)
Age (years)
At diagnosis 80 (100) 62.2 1.3 (36.7–96.4)
At end of follow up 80 (100) 67.5 1.5 (38.8–97.2)
Follow up time (years) 80 (100) 5.3 0.4 (0.6–14.4)
Other characteristics
Body-Mass Index (kg/m2) 80 (100) 29.1 0.9 (19.6–57.3)
Number of children (parity) 56 (70) 2.0 0.2 (0–6)
Radiographic characteristics (qualitative)
Calcified 37 (56.1)
Perilesional edema 5 (6.3)
T2-hyperintense 35 (43.8)

Comparison of the e-HRT and no-HRT groups; continuous variables showed a normal distribution and Student's independent-sample two-tailed T-tests were used; categorical variables were compared using Fisher’s exact test (1-sided).

*Significant.